INT1728

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1979
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 36
Total Number 37
Disease Relevance 3.76
Pain Relevance 25.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Cndp2) peptidase activity (Cndp2) cytoplasm (Cndp2)
Anatomy Link Frequency
brain 5
vas deferens 3
tail 2
small intestine 1
molar 1
Cndp2 (Mus musculus)
Pain Link Frequency Relevance Heat
Cholecystokinin 3 99.92 Very High Very High Very High
narcan 109 99.90 Very High Very High Very High
Analgesic 197 99.84 Very High Very High Very High
opioid receptor 160 99.82 Very High Very High Very High
Intracerebroventricular 12 99.72 Very High Very High Very High
analgesia 93 99.68 Very High Very High Very High
tail-flick 50 99.64 Very High Very High Very High
antagonist 34 99.64 Very High Very High Very High
Opioid 123 99.42 Very High Very High Very High
antinociception 123 99.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nociception 34 99.72 Very High Very High Very High
Sprains And Strains 6 99.40 Very High Very High Very High
Pain 63 98.44 Very High Very High Very High
Obesity 42 98.22 Very High Very High Very High
Targeted Disruption 35 88.00 High High
Urological Neuroanatomy 8 88.00 High High
Toxicity 36 83.68 Quite High
Cancer 22 79.68 Quite High
Apoptosis 8 79.44 Quite High
Anaemia 2 79.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The hydrolysis of the substrate was linear with time and was strongly inhibited by two irreversible inhibitors of cysteine peptidases (E64 and K11777), all at a concentration of 10 ?
Negative_regulation (inhibitors) of peptidase
1) Confidence 0.57 Published 2006 Journal Proteome Sci Section Body Doc Link PMC1462989 Disease Relevance 0 Pain Relevance 0
Furthermore intrastriatal administration of kainic acid as well as interruption of the nigrostriatal dopaminergic pathway by 6-hydroxydopamine (6-OHDA) lead to similar decreases in this peptidase activity and in the number of opiate receptors.
Negative_regulation (decreases) of peptidase associated with opiate
2) Confidence 0.56 Published 1979 Journal Neurosci. Lett. Section Abstract Doc Link 229439 Disease Relevance 0 Pain Relevance 0.61
The Analgesic Activity of Bestatin as a Potent APN Inhibitor

Bestatin, a small molecular weight dipeptide, is a potent inhibitor of various aminopeptidases as well as LTA4 hydrolase.

Negative_regulation (inhibitor) of peptidase associated with analgesic
3) Confidence 0.42 Published 2010 Journal Frontiers in Neuroscience Section Title Doc Link PMC2903224 Disease Relevance 0.30 Pain Relevance 0.18
They studied the inhibitory change on ICSS after the administration of Bestatin and Thiorphan, two specific inhibitors of the peptidases that inactivate NM and NT, respectively, obtaining the result that microinjections of Bestatin and Thiorphan potentiated the inhibition of ICSS produced by the intracortical administration of NM and NT, correspondingly.
Negative_regulation (inhibitors) of peptidase
4) Confidence 0.42 Published 2010 Journal Frontiers in Neuroscience Section Body Doc Link PMC2903224 Disease Relevance 0 Pain Relevance 0.72
Free-living and parasitic nematodes also possess neprilysin-like peptidases that cleave peptide bonds N-terminal to hydrophobic residues and are inhibited by phosphoramidon [19-22].
Negative_regulation (inhibited) of peptidase
5) Confidence 0.42 Published 2008 Journal BMC Evol Biol Section Body Doc Link PMC2259306 Disease Relevance 0.23 Pain Relevance 0.06
The majority of the vertebrate M13 peptidases delineate into functionally related clusters representing the PHEX, Kell, ECE-1, ECE-2, ECEL1, neprilysin and MMELLII groups of peptidases (Figure 2 I-V).
Negative_regulation (groups) of peptidase
6) Confidence 0.41 Published 2008 Journal BMC Evol Biol Section Body Doc Link PMC2259306 Disease Relevance 0 Pain Relevance 0
PSA inhibition was achieved using two unrelated small molecular weight compounds: bestatin, a natural, slow binding, competitive inhibitor of many aminopeptidases (35), and PAQ-22, a synthetic, non-competitive inhibitor that does not act as a substrate-mimic and binds to PSA at a distinct site (36–38).
Negative_regulation (inhibitor) of peptidase
7) Confidence 0.41 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2972693 Disease Relevance 0.29 Pain Relevance 0
Various peptidase inhibitors significantly inhibited the catabolism of co-administered substance P.
Negative_regulation (inhibitors) of peptidase associated with substance p
8) Confidence 0.38 Published 1990 Journal Neuroscience Section Abstract Doc Link 1699171 Disease Relevance 0 Pain Relevance 0.98
The antinociceptive activity of dermorphin was significantly enhanced when the heptapeptide was injected simultaneously with both peptidase inhibitors.
Negative_regulation (inhibitors) of peptidase associated with antinociceptive
9) Confidence 0.36 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1352249 Disease Relevance 0.08 Pain Relevance 0.43
The dissociated and opposite effects of peptidase inhibitors and naloxone per se might reflect a variable participation of endogenous enkephalins (or other opioid peptides) in the control of various nociceptive responses.
Negative_regulation (inhibitors) of peptidase associated with nociception, narcan, enkephalin and opioid
10) Confidence 0.36 Published 1986 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3519246 Disease Relevance 0.17 Pain Relevance 1.15
A wide range of potencies was observed, both in the control state and in the presence of peptidase inhibition.
Negative_regulation (inhibition) of peptidase
11) Confidence 0.35 Published 1991 Journal Life Sci. Section Abstract Doc Link 1847736 Disease Relevance 0 Pain Relevance 1.00
This first direct evidence of analgesia resulting from peptidase inhibition, in the tail flick test with mice and rats, hot plate (paw lick) and TES shows that the pain suppressive effects of endogenous opioid peptides are not restricted to naloxone-facilitated noxious stimuli but occur more generally, in all morphine-sensitive tests.
Negative_regulation (inhibition) of peptidase in TES associated with pain, narcan, endogenous opioid, tail-flick, morphine and analgesia
12) Confidence 0.32 Published 1991 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2032557 Disease Relevance 0.10 Pain Relevance 1.70
Radiolabeled Leu-enkephalin also did not accumulate intracellularly, even if degradation of the peptide was prevented by use of peptidase inhibitors.
Negative_regulation (inhibitors) of peptidase associated with enkephalin
13) Confidence 0.28 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 3612123 Disease Relevance 0 Pain Relevance 0.19
The differential effects of RB 38A in the various assays is likely to be related to the amount of enkephalins released and to the efficiency of peptidase inactivation in particular brain regions implicated in the control of a given nociceptive input.
Negative_regulation (inactivation) of peptidase in brain associated with nociception and enkephalin
14) Confidence 0.28 Published 1991 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2032557 Disease Relevance 0.18 Pain Relevance 1.27
Several peptides of diverse structure, reported to possess high affinity and selectivity for the delta opioid receptor, were studied using the mouse isolated vas deferens preparation to determine the effect of peptidase inhibition on their apparent potency.
Negative_regulation (inhibition) of peptidase in vas deferens associated with opioid receptor and potency
15) Confidence 0.26 Published 1991 Journal Life Sci. Section Abstract Doc Link 1847736 Disease Relevance 0 Pain Relevance 0.85
In the presence of peptidase inhibition, deltorphin II was the most potent peptide tested (IC50 = 1.13 x 10(-10) molar), and as such is the most potent delta opioid agonist reported to date.
Negative_regulation (inhibition) of peptidase in molar associated with mu agonist
16) Confidence 0.26 Published 1991 Journal Life Sci. Section Abstract Doc Link 1847736 Disease Relevance 0 Pain Relevance 0.93
Both the degradation of endomorphin-2 and the accumulation of major metabolites were inhibited by specific inhibitors of dipeptidyl peptidase IV, such as diprotin A and B.
Negative_regulation (inhibitors) of peptidase
17) Confidence 0.24 Published 2003 Journal Biochem. Pharmacol. Section Abstract Doc Link 12906930 Disease Relevance 0 Pain Relevance 0.13
Role of endogenous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice (C57BL/6J and DBA/2J).
Negative_regulation (inhibitors) of peptidase associated with nociception, analgesic, enkephalin and sprains and strains
18) Confidence 0.22 Published 1989 Journal Neuropharmacology Section Title Doc Link 2716968 Disease Relevance 0.37 Pain Relevance 0.70
The absorption rate (clearance) of CcpLEamide was comparable with that of CcpLE in the presence of these peptidase inhibitors.
Negative_regulation (inhibitors) of peptidase
19) Confidence 0.19 Published 1998 Journal Biopharm Drug Dispos Section Abstract Doc Link 9872343 Disease Relevance 0 Pain Relevance 0.80
Both the degradation of endomorphin-2 and the accumulation of major metabolites were inhibited by specific inhibitors of dipeptidyl peptidase IV, such as diprotin A and B.
Negative_regulation (inhibitors) of peptidase
20) Confidence 0.18 Published 2004 Journal Yakugaku Zasshi Section Abstract Doc Link 15297724 Disease Relevance 0 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox